Summary Cell growth survival studies have revealed that 7-OH methotrexate is two orders of magnitude less cytotoxic to human melanoma and human acute lymphoblastic leukaemia (ALL) cells in vitro than methotrexate. The influence of 7-OH methotrexate on methotrexate toxicity was investigated by studying cell growth in the presence of methotrexate and its 7-OH metabolite and by studying [3H] In a previous study it was shown that two factors may contribute to the continued survival of tumour cells in vivo from the effects of high-dose methotrexate therapy with leucovorin rescue. These two factors were: 1. The concentration of 7-OH methotrexate in plasma which may be sufficient to inhibit the further uptake of methotrexate. 2. The rescue agent leucovorin which may salvage both host tissue and viable tumour cells from the toxic effects of methotrexate.
In a previous study it was shown that two factors may contribute to the continued survival of tumour cells in vivo from the effects of high-dose methotrexate therapy with leucovorin rescue. These two factors were: 1. The concentration of 7-OH methotrexate in plasma which may be sufficient to inhibit the further uptake of methotrexate. 2. The rescue agent leucovorin which may salvage both host tissue and viable tumour cells from the toxic effects of methotrexate.
This study reports on the role that the 7-OH metabolite of methotrexate may have in affording protection to tumour cells against methotrexate. To date this aspect of methotrexate therapy has received limited attention (Lankelma et al., 1980) and the major concern for this metabolite is for its role in renal toxicity during high dose therapy (Jacobs et al., 1976) .
The effect of methotrexate on the toxicity to human melanoma and human acute lymphoblastic leukaemia (ALL) cells in the presence of 7-OH methotrexate was investigated. A companson was made of the melanoma cell lines ADLER, B8 and BlO with the ALL cell line KM3, which was reported to be methotrexate sensitive in vivo (Schnieder et al., 1977 (Gaukroger et al., 1983 ).
Materials and methods
The cell lines used and cell culture techniques employed were given previously (Gaukroger et al., 1983) . Radiolabelled (Gaukroger et al., 1983) and only details of the efflux measurements will be given here. For unidirectional measurement of fluxes, simple integrated, rate-equation plots were performed (Eilam & Stein, 1973 Figure 1 for the melanoma cell lines B8 and ADLER, and for the ALL cell line KM3. The B8 and KM3 cell lines exhibited a transition from survival (>20%) to toxicity to MTX at 10-9/10-8M whereas this occured at 10-8/10-7M for the ADLER cell line.
7-OH methotrexate The same three cell lines as above were exposed to various concentrations of 7-OH MTX as indicated and dose response profiles obtained which exhibited a survival/toxicity cut-off point at 10-7/10-6M for KM3 and 10-6/10-5M for B8 and ADLER ( following incubation of the ALL cell line, KM3, in the absence or presence of 7-OH methotrexate. The effect of 1 iM 7-OH MTX on uptake of [3H]-MTX by the KM3 cell line was minimal whereas the effect of 100 MM 7-OH MTX was greater and essentially the same for both melanoma and ALL cell lines (Gaukroger et al., 1983) . If the data for the uptake of [3H]-MTX is plotted as a first order reaction then a straight line relationship becomes apparent for the initial uptake period (Figure 6 ). This allows calculation of initial uptake rates of [3H]-MTX for the ALL and melanoma (138 & 125 dpm min-1) in the absence of extracellular 7-OH MTX. In the presence of this metabolite the decrease in the rate of uptake is greater for the melanoma (70 dpm min 1) than for the ALL (128 dpm min -1). (Gaukroger et al., 1983) (Goldman, 1975) Gaukroger et al., 1983) which will tend to maintain intracellular methotrexate levels. (Fabre et al., 1983; and which in combination with a short cell cycle may lead to exhaustion of reduced folate and rapid cell death (Jacobs et al., 1975 (Gaukroger et al., 1983) but have been identified in ALL cells (Fabre et al., 1983) . In conclusion, 7-OH MTX interferes with toxicity of MTX to melanoma cells. MTX is rapidly lost from melanoma cells (possibly due to the lack of polyglutamate formation) when compared to an ALL and less drug is retained within cells in the presence of 7-OH MTX as a result of inhibited entry and enhanced exit of methotrexate. It was shown previously (Gaukroger et al., 1983 ) that 7-OH MTX levels in plasma approached 10-5M about 8 h from the start of an infusion and exceeded MTX levels about 4/5 h later. Unless cells show irrevocable damage within this time scale it is possible, for the reasons outlined above, that 7-OH MTX salvages cells from MTX toxicity until rescue by leucovorin occurs.
